Next Post

NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results

New data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall Survival reaching 23 months in evaluable patients; Data with minimum follow-up of one year for full study population anticipated in mid-2023 Pivotal Phase III study, NANORAY-312, now actively enrolling elderly, […]